Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228011 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2817760 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL14199486 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL662016 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13497166 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL18533110 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9999673 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12154805 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8045018 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9843877 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2018089786-A1 | ATG7 INHIBITORS AND THE USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO, S.P.A. (IT) | 2007-04-12 | — | — | US | disclosed |
| US-20050228175-A1 | Production method of 2-deoxy-L-ribose compound | AJINOMOTO CO., INC. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1574515-A2 | Production method of 2-deoxy-L-ribose compound | Ajinomoto Co., Inc. (JP) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228175-A1 | Production method of 2-deoxy-L-ribose compound | RNASEL, DERA, RPIA | OGA 430/4885PIM1 1417/4885CSNK2A2 2894/4885 |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | OGA 3859/4885PIM1 2981/4885CSNK2A2 457/4885 |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | RNGTT, RNASEL, CPSF7 | OGA 209/4885PIM1 2119/4885CSNK2A2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.